GlassScriptPhysician profile
Mohammed Gibreal
NPI 1710242086
$10,783.40
in general payments reported to CMS, 2019-2025
37 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $351 · 2021: $6,102 · 2022: $196 · 2023: $801 · 2024: $1,777 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,577.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,390.77 | 2021-2023 | Micra |
| Boston Scientific Corporation | $862.01 | 2019-2025 | Watchman Flx, Accolade Sr, Watchman |
| Janssen Pharmaceuticals, INC | $573.17 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $547.41 | 2022-2025 | |
| Amgen INC. | $361.87 | 2019-2025 | Repatha, Repatha, Prolia |
| Pfizer INC. | $327.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $302.26 | 2023-2025 | Verquvo, Steglatro, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $284.48 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $279.98 | 2021-2024 | Cardiomems |
| Heartflow, INC. | $279.12 | 2023-2025 | Ffrct |
| Baylis Medical Company INC | $246.23 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $196.70 | 2019-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.84 | 2019-2021 | |
| Cvrx, INC. | $139.09 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $93.30 | 2023-2024 | Inpefa |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $83.49 | 2023-2025 | Amvuttra, Onpattro |
| Novo Nordisk INC | $80.02 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Philips North America LLC | $61.44 | 2023-2024 | (Ck4) Mcot |
| Takeda Pharmaceuticals U.S.A., INC. | $60.30 | 2022-2023 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $58.91 | 2019-2023 | Evkeeza, Dupixent |
| Amarin Pharma, INC. | $43.44 | 2019 | |
| Lilly USA, LLC | $37.10 | 2022-2025 | Zepbound |
| Genzyme Corporation | $34.32 | 2022-2023 | |
| Medicomp INC | $34.04 | 2025 | Telepatch Cardiac Monitor |
| Esperion Therapeutics, INC. | $32.73 | 2024-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $29.15 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $26.46 | 2024 | Optimizer |
| Inspire Medical Systems, INC. | $19.32 | 2024 | Inspire |
| Ionis Pharmaceuticals, INC. | $18.40 | 2025 | Tryngolza |
| Exact Sciences Corporation | $18.38 | 2024 | Cologuard Collection Kit |
| Taiho Oncology, INC. | $17.89 | 2023 | |
| Bridgebio Pharma, INC. | $17.67 | 2025 | Attruby |
| Agios Pharmaceuticals, INC. | $16.71 | 2023 | Pyrukynd |
| Janssen Biotech, INC. | $16.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.35 | 2019 | |
| Biosense Webster, INC. | $13.71 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $12.99 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Gibreal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.